Conferences & Events

17TH CONGRESS OF ECCO
February 16–19, 2022

 

Disclaimer: This page is for Health Care Professionals only.

Galapagos @ ECCO'22

 

The annual European Crohn’s and Colitis Organisation (ECCO) Congress is the biggest event in the inflammatory bowel disease calendar. The ECCO'22 scientific programme includes a wide range of sessions presented by some of the world’s top specialists, exploring basic science, traditional medicine and clinical practice, as well as a wealth of important new data!

Galapagos is proud to be a sponsor at ECCO'22 and to be delivering an interactive live symposium, as well as a range of other exciting activities throughout the congress. We look forward to meeting you at ECCO'22!

Symposium

Date: February 17, 2022
Time: 18:45–19:45

 

Join Professors Iris Dotan, Séverine Vermeire and Gionata Fiorino, plus a host of special guests, for the Galapagos-sponsored satellite symposium at the 17th Congress of the European Crohn’s and Colitis Organisation (ECCO’22)
 

We may be going virtual, but we are still bringing you an unmissable event!

Gain practice-focused knowledge

In a series of discursive, case-based presentations, our expert faculty will:

  • Explore the thoughts of a multidisciplinary team on managing patient burden in UC
  • Examine the importance of alignment between patients and healthcare professionals when setting treatment goals, as part of a holistic approach to remission
  • Review key data, practical considerations and expert experience with preferential JAK1 inhibitors as a new treatment option for UC

Learn from seven outstanding speakers

Throughout this event, our speakers will be joined by several special guests. IBD nurse specialist and IBD patient Kay Greveson will share her experiences of living with IBD, while Professor Dotan will bring together several members of her multidisciplinary team, including dietician Dr Lihi Godny and IBD nurse specialist Revital Barkan, to provide their perspectives on how to tackle a challenging patient case.


Have your chance to guide discussion

As well as hearing from this internationally renowned panel, our interactive agenda allows you to guide the discussion by voting for the specialties and topics of most interest to you for the MDT segment.

Don’t miss out! Join us at 18:45 CET on Thursday 17 February 2022 to gain insights from experts and ask them your questions.

  This programme is not affiliated with ECCO


Sign up for Galapagos news & views


Would you like to receive updates via email on Galapagos' activities and services?

Symposium Speakers

Professor Iris Dotan (Chair)
Director, Division of Gastroenterology, Rabin Medical Center, Petah Tikva, Israel

Prof. Iris Dotan’s research interests lie in biomarker-based stratification of patients with IBD, personalised treatment and care, biologics, and novel therapies. Her translational research explores mucosal immunology, focussing on the interactions of intestinal epithelial cells and mucosal lymphocytes with their environment. She is Past President of the Israeli Association of Gastroenterology and Liver Diseases, Vice Chair of the International Organization for the Study of Inflammatory Bowel Disease (IOIBD), a member of ECCO and the Scientific Committee of UEG, and the founder of the Israeli IBD Research Nucleus.


Professor Séverine Vermeire 
Professor of Medicine, Universitair Ziekenhuis Leuven, Belgium 

Prof. Séverine Vermeire obtained her MD and PhD at KU Leuven and has also trained at the National University of Asuncion, Paraguay, the Wellcome Centre for Human Genetics, UK, and Montreal General Hospital, Canada. Since 2003, she has been a staff member at the Gastroenterology Department of University Hospitals Leuven and is Professor of Medicine at KU Leuven, becoming Head of the Department of Chronic Diseases and Metabolism in 2016. Prof. Vermeire has been a principal investigator in several randomised controlled trials with new therapeutic compounds. Her work, which focuses on the role of the microbiome, genetic susceptibility in IBD and signatures predictive of therapy response, has led to over 500 peer-reviewed articles.


Professor Gionata Fiorino, MD, PhD
Senior gastroenterologist and clinical researcher, Department of Gastroenterology and Digestive Endoscopy, San Raffaele Hospital and Vita-Salute San Raffaele University, Milan, Italy

Prof. Gionata Fiorino completed his medical degree in 2004, specialised in gastroenterology in 2009 and obtained his PhD in 2013. His research focusses on early diagnosis, non-invasive monitoring, imaging techniques, novel therapies and biosimilars, and quality of care in IBD. He has collaborated on over 230 peer-reviewed articles and has recently coordinated the first GRADE-based ECCO Guidelines on Therapeutics in Crohn’s Disease and the first ECCO Consensus on Quality of Care Standards in IBD. He is currently Chair of the Scientific Committee of the Italian Group for the study of IBD and Associate Editor of the Journal of Crohn’s and Colitis.

Abstracts


Re-treatment with filgotinib in patients with Ulcerative Colitis following treatment interruption: Analysis of the SELECTION and SELECTIONLTE studies

Séverine Vermeire, Brian Feagan, Laurent Peyrin-Biroulet, Alessandra Oortwijn, Margaux Faes, Angela de Haas and Gerhard Rogler



Efficacy and safety of filgotinib in patients with Ulcerative Colitis stratified by age: Post hoc analysis of the phase 2b/3 SELECTION and SELECTIONLTE studies

Stefan Schreiber*, Edward V Loftus Jr*, Christian Maaser, Silvio Danese, Christine Rudolph, Rob Jongen, Angela De Haas, Alessandra Oortwijn and Séverine Vermeire

Session time (CET):

Presentation time (CET):




Efficacy and safety outcomes of long-term treatment with filgotinib 200 mg among patients with Ulcerative Colitis: An interim analysis of SELECTIONLTE

Brian Feagan, Katsuyoshi Matsuoka, Gerhard Rogler, Margaux Faes, Alessandra Oortwijn, Angela de Haas, Christine Rudolph, Haridarshan Patel and Laurent Peyrin-Biroulet



Efficacy and safety of filgotinib for the treatment of perianal fistulizing Crohn’s disease: results from the phase 2 DIVERGENCE 2 study

Walter Reinisch, Jean-Frederic Colombel, Geert R D’Haens, Jordi Rimola, Angela DeHaas-Amatsaleh, Matt McKevitt, Xuehan Ren, Adrian Serone, David A Schwartz and Krisztina B Gecse
Virtual session: Navigating the Oceans of IBD - Scientific Session 6: Do we see light at the end of the fistula track?
Oral presentation Number: OP18
Link to Abstract: European Crohn´s and Colitis Organisation - ECCO - OP18 Efficacy and safety of filgotinib for the treatment of perianal fistulizing Crohn’s Disease: Results from the phase 2 DIVERGENCE 2 study (ecco-ibd.eu)
Date: 18 February 2022

Session time (CET):

Presentation time (CET):


Exploring disease control by combining clinical, biological, and health-related quality of life remission with endoscopic improvements among Ulcerative Colitis patients treated with filgotinib: A post-hoc analysis from the SELECTION trial

Stefan Schreiber, Brian Feagan, Laurent Peyrin-Biroulet, Severine Vermeire, Margaux Faes, Kristina Harris, Alessandra Oortwijn, Patrick Daniele, Haridarshan Patel and Silvio Danese

Session time (CET):

Presentation time (CET):




Indicators for inadequate response among patients with Ulcerative Colitis treated with advanced therapies in German clinical practice

Bernd Bokemeyer, Nils Picker, Daniel Kromer, Ludger Rosin and Haridarshan Patel



Indicators for inadequate response to advanced therapy in patients with Ulcerative Colitis: results from a medical chart review in the United Kingdom

James Oliver Lindsay, Nils Picker, Daniel Kromer, Michael Smyth and Haridarshan Patel

Rates of clinical remission among patients with Ulcerative Colitis from real-world clinical practice settings from Germany

Bernd Bokemeyer, Nils Picker, Daniel Kromer, Ludger Rosin and Haridarshan Patel



Insights from patients with Ulcerative Colitis on disease burden: Findings from a real-world survey in Europe

Johan Michael Burisch, Ailsa Hart, Alessandra Oortwijn, Javaria Mona Khalid, Fritha Hennessy, Hannah Knight, Rachael Meadows, Haridarshan Patel and Alessandro Armuzzi
E-Poster Number: P293
Link to Abstract: European Crohn´s and Colitis Organisation - ECCO - P293 Insights from patients with Ulcerative Colitis on disease burden: Findings from a real-world survey in Europe (ecco-ibd.eu)
E-poster available to view in online platform from 16 February until May 2022*

Related

ECCO'22 VIRTUAL CONGRESS!

Join us in the virtual congress from February 16-19, 2022 at 18.45 CET.

Discover the role of the JAK-STAT pathway in UC